- Home
- HPQ vs BBIO Comparison
HPQ vs BBIO Comparison
Compare HPQ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPQ | BBIO |
|---|---|---|
| Founded | 1939 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 15.9B |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HPQ | BBIO |
|---|---|---|
| Price | $28.12 | $82.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 25 |
| Target Price | $21.42 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 14.7M | 3.0M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $55,295,000,000.00 | $502,076,000.00 |
| Revenue This Year | $3.10 | $89.45 |
| Revenue Next Year | $0.39 | $73.78 |
| P/E Ratio | $26.62 | ★ N/A |
| Revenue Growth | 3.24 | ★ 126.26 |
| 52 Week Low | $17.56 | $45.42 |
| 52 Week High | $29.65 | $93.42 |
Technical Indicators
Market Signals| Indicator | HPQ | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 56.36 |
| Support Level | $18.00 | $78.98 |
| Resistance Level | $29.65 | $85.34 |
| Average True Range (ATR) | 1.14 | 2.27 |
| MACD | 0.25 | -0.65 |
| Stochastic Oscillator | 83.21 | 47.73 |
Price Performance
Historical ComparisonAbout HPQ HP Inc.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.